Companies: 10,795·Total market cap: $144.5T
Gamida Cell Ltd.

Gamida Cell Ltd.

GMDANASDAQHealthcare
$0.03
+$0.00(+0.00%)
Market Cap$4337295
P/E Ratio
52W High$0.0395
52W Low$0.0327
Overview

Gamida Cell Ltd. (GMDA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

gmda · pe ratio · data through Dec 31, 2023

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Gamida Cell Ltd. (GMDA) measures how much investors pay for each dollar of the company's trailing earnings. GMDA's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$0.42.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31

Forward P/E
0.04x
FY2026 est. EPS $0.90
Based on 1 analyst
EPS (TTM)
-$0.42
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Gamida Cell Ltd. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-15

PE Ratio History

2016 – 2023 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Gamida Cell Ltd.
Gamida Cell Ltd.You
GMDA
$4MN/A-$0.42
Aptose Biosciences Inc.
Aptose Biosciences Inc.
APTO
$4MN/A$0.00
Atreca, Inc.
Atreca, Inc.
BCEL
$4MN/A-$2.52
Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd.
CYTO
$1MN/A$0.00
Gritstone bio, Inc.
Gritstone bio, Inc.
GRTS
$4MN/A-$1.20
Hillstream BioPharma, Inc.
Hillstream BioPharma, Inc.
HILS
$4MN/A-$1.12
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
IDRA
$0MN/A-$7.17

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2023-12-31Latest
FY2023
$-0.42
2022-12-31
FY2022
$-2.42
2021-12-31
FY2021
$-1.56
2020-12-31
FY2020
$-1.75
2019-12-31
FY2019
$-1.17
2018-12-31
FY2018
$-2.12
2017-12-31
FY2017
$-1.06
2016-12-31
FY2016
$-1.26

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Gamida Cell Ltd. (GMDA) measures how much investors pay for each dollar of the company's trailing earnings. GMDA's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$0.42.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.03 ÷ -$0.42 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

GMDA pe ratio · 6 questions

GMDA's current PE ratio is N/A as of 2026-06-15, based on a stock price of $0.03 and TTM EPS of -$0.42. Data sourced from Financial Modeling Prep via GMDA's SEC 10-K and 10-Q filings.

GMDA PE ratioWhat is GMDA PE ratioCurrent PE ratio of GMDAGMDA PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Gamida Cell Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15